Other penile/urethral cancer highlights from AUA 2018 included analyses of fludeoxyglucose positron emission tomography-computed tomography and the Pl3K-AKT-mTOR pathway.
Active surveillance in selected patients with localized renal masses 4 cm to 7 cm and a patient-derived xenograft system for predicting response to targeted and immune therapies in patients with metastatic RCC were among other noteworthy kidney cancer studies presented at AUA 2018.
Other bladder cancer take-home messages covered topics such as artificial intelligence and deep learning for staging of T1 disease as well as a wearable fitness tracker for collecting data on physical activity after radical cystectomy.
Three new clinical guidelines, potentially practice-changing advances in robotics and artificial intelligence, and research on hot-button public health issues such as opioid abuse were among many highlights of the AUA annual meeting in San Francisco.
A recent large, population-based comparative analysis examined outcomes for patients treated with percutaneous ablation, partial nephrectomy, or radical nephrectomy.
A new frailty assessment tool can aid in the prognosis of urologic cancer patients, its inventors say.
A mobile app for stone metaphylaxis and an algorithm defining specific indications for stent omissions were among the other highlights in endourology/stones at AUA 2018.
The AUA 2018 take-home messages for BPH/LUTS also encompassed multiple treatment approaches for BPH as well as combination therapies for LUTS.
Other key prostate cancer studies from AUA 2018 included updated survival data from the European Randomized Study of Screening for Prostate Cancer and a multicenter trial of MRI-targeted biopsy.
Recent studies point to the significant potential activity trackers hold in urology.